Skip to main content
NCBI home page
Oncology Research logoLink to Oncology Research
. 2018 May 7;26(4):637–644. doi: 10.3727/096504017X15112639918174

miR-767-3p Inhibits Growth and Migration of Lung Adenocarcinoma Cells by Regulating CLDN18

Yi Long Wan *, Han Jue Dai †, Wei Liu ‡, Hai Tao Ma *
PMCID: PMC7844711  PMID: 29169410

Abstract

Claudin18 (CLDN18) is necessary for intercellular junctions and is reported to be involved in cell migration and metastasis, making it like an oncogene in various cancer types. However, the biological function and regulatory mechanisms of CLDN18 in lung adenocarcinoma are not yet clear. In this study, we found downregulation of miR-767-3p and upregulation of CLDN18 in lung adenocarcinoma tissue and cell lines. In addition, there was a negative correlation between the expression of miR-767-3p and CLDN18 in lung adenocarcinoma. Double luciferase reporter gene analysis showed that miR-767-3p modulates the expression of CLDN18 by binding its 3′-untranslated regions (3′-UTR). Knockdown of CLDN18 results in a decrease in the growth, migration, and invasion of lung adenocarcinoma cells. Although overexpression of miR-767-3p inhibits lung adenocarcinoma cell growth and migration, these effects can be rescued by reexpressing CLDN18. In summary, the data suggest that miR-767-3p inhibits tumor cell proliferation, migration, and invasion by targeting CLDN18, providing a promising therapeutic target for lung adenocarcinoma.

Key words: miR-767-3p, Lung adenocarcinoma, Claudin 18 (CLDN18), Migration, Invasion

INTRODUCTION

As one of the most common malignancies, lung cancer is the leading cause of cancer-related deaths worldwide. Lung adenocarcinoma is the most common type of lung cancer, accounting for ∼35% of primary lung cancers1. Although there have been recent advances in the diagnosis of and treatment strategies for lung cancer, a significant proportion of patients with lung adenocarcinoma will eventually die; the 5-year overall survival rate is about 11%2. Therefore, it is urgent to clarify the molecular mechanism of the development of lung adenocarcinoma and identify new prognostic markers and molecular therapeutic targets to improve the diagnosis and treatment of lung adenocarcinoma.

MicroRNAs (miRNAs) are a small class of noncoding RNAs (about 20–23 nucleotides) that regulate the expression of their target genes through binding to 3′-untranslated regions (3′-UTRs) at posttranscriptional levels3. Substantial studies have shown that dysregulated miRNAs are involved in a variety of biological and pathological processes, including tumor cell proliferation, survival, apoptosis, and tumorigenesis.4,5 miRNAs commonly function as tumor suppressors or oncogenes, which play crucial roles in the development and progression of various cancers6. Recent research identified 21 miRNAs as cancer genes and 7 miRNAs as tumor suppressors in lung adenocarcinoma using high-throughput sequencing analysis7. Moreover, miR-483-5p upregulation is associated with progression of lung adenocarcinoma through promoting tumor cell epithelial–mesenchymal transition (EMT) as an oncogene8. Previously, miR-767, as an oncogene, was shown to accelerate cell proliferation and metastasis of several cancers, including bladder cancer, gastric cancer, and prostate cancer9. However, the expression and role of miR-767-3p in lung adenocarcinoma remain unclear.

In the present study, we demonstrated that miR-767-3p is downregulated in lung adenocarcinoma patients and cell lines, and negatively correlated with claudin 18 (CLDN18) expression. Upregulation of miR-767-3p inhibits tumor growth and migration by reducing the expression levels of CLDN18. These results identified a new axis consisting of miR-767-3p and CLDN18 for controlling tumor growth and migration in lung adenocarcinoma.

MATERIALS AND METHODS

Tissues and Cell Culture

A total of 39 lung adenocarcinoma tissues and normal tissues were collected from The First Affiliated Hospital of Soochow University (Jiangsu, P.R. China). Patients were proven to be suffering from lung adenocarcinoma and received chemotherapy or radiotherapy. Cell lines of lung adenocarcinoma (H1975, HCC827, H1650, and H441), and SV40-immortalized nontumorigenic human bronchial epithelial cells (BEAS-2B) used as a control, were obtained from the Chinese Academy of Sciences Cell Bank of Type Culture Collection (CBTCCCAS, Shanghai, P.R. China). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) or Roswell Park Memorial Institute (RPMI)-1640 medium, which was supplemented with 10% fetal bovine serum (FBS) and 100 mg/ml streptomycin/penicillin. Cells were maintained in a humidified atmosphere of 5% CO2 at 37°C.

RNA Isolation and Qualitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR)

Total RNA was extracted from lung adenocarcinoma specimens and cell lines by TRIzol reagent (Invitrogen, CarIsbad, CA, USA). PCR was performed using the SYBR Green PCR Kit (Invitrogen) from Applied Biosystems (Foster City, CA, USA). The following were the primers used: CLDN18, 5′-ACATGCTGGTGACTAACTTCTG-3′ (forward) and 5′-AAATGTGTACCTGGTCTGAACAG-3′ (reverse); glyceraldehydes 3-phosphate dehydrogenase (GAPDH), 5′-CTCACCGGATGCACCAATGTT-3′ (forward) and 5′-CGCGTTGCTCACAATGTTCAT-3′ (reverse). TaqMan MicroRNA Assay was used to reverse the translation of RNA. YM500v2 meta-analysis (http://ngs.ym.edu.tw/ym500v2/index.php) was performed to determine miRNA expression in lung adenocarcinoma specimens and normal tissue. After identifying miR-767-3p as an miRNA whose expression was significantly altered in lung adenocarcinoma, TargetScan (http://www.targetscan.org) was used to investigate potential binding partners.

Western Blot and Immunohistochemistry Staining Assay

Target protein expression was assessed by Western blotting analysis of total cell lysates in radioimmunoprecipitation assay (RIPA) buffer in the presence of rabbit antibodies to CLDN18 and β-actin (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The signal was analyzed using the chemiluminescence detection system (Millipore, Braunschweig, Germany) and visualized with the ChemiDoc XRS system (Bio-Rad, Hercules, CA, USA). In immunohistochemistry (IHC) assays, the samples were cut into 4-mm slices. The tissue samples were incubated with CLDN18 antibody and then photographed with an Olympus microscope (Tokyo, Japan).

Luciferase Assay

Mutant (MUT) and wild-type (WT) sequences of CLDN18 3′-UTR were amplified by PCR and cloned into control vector. 293T, H195, and HCC827 cells were cotransfected with WT or MUT of CLDN18 3′-UTR, miR-767-3p, or a negative control miR (miR-NC). Cells were obtained 48 h after transfection. The luciferase activity was performed using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA).

Cell Proliferation Assays

Cell viability was analyzed by CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega). Briefly after transfection, cells were seeded in 96-well cell culture plates and cultured for 24, 48, 72, and 96 h. Then 20 μl of One Solution reagent was added to the 96-well cell culture plates and incubated for 4 h. The absorbance was measured at 490 nm using a Synergy™ HT multimode microplate reader (Bio-Tek, Winooski, VT, USA)10.

Wound Healing Migration Assay

Cells (1 × 105 H1975 or HCC827) were seeded into six-well plates. The confluent monolayers of cells were scratched with a 200-μl pipette tip, and the wound closures of cells were observed by measuring the size of the initial wound and comparing the size of the wound after 24 h11.

Transwell Invasion Assay

Cell invasion was performed using Transwell chambers. Cells were seeded in the upper Transwell chamber of 24-well plates containing serum-free medium. The lower chamber contained medium with 10% serum for 24 h. The invasion cells at the bottom of the chamber were stained and counted12.

In Vivo Assay

H1975 cells were transfected with control short hairpin RNA (shRNA; shControl) or shCLDN18. Two-week-old mice (SLAC Laboratory Animal Co. Ltd., Shanghai, P.R. China) were subcutaneously inoculated with 0.1 ml of a 1 × 106 H1975 cell suspension (six mice per group). Every 3 days, measurements were made to assess tumor volume and calculate tumor volume by the formula (length × width2)/213. Mice were sacrificed after 25 days.

Statistical Analysis

A Student’s t-test and one-way ANOVA was performed to analyze the two different groups. Data represent means ± SD of three separate experiments. Statistical analyses were performed by the GraphPad Prism 5 software. A value of p < 0.05 was considered statistically significant.

RESULTS

miR-767-3p Was Downregulated in Lung Adenocarcinoma

YM500v2 meta-analysis was performed to identify miRNAs that were differentially expressed in lung adenocarcinoma tissue and normal solid tissue (Fig. 1A). A total of 2,578 miRNAs were significantly altered in lung adenocarcinoma (1,697 were upregulated and 881 were downregulated) compared to normal tissue. Of the 1,697 upregulated miRNAs, 613 miRNAs were identified as upregulated to infinitely increased levels compared to the very low expression levels in the normal group of these miRNAs. In the 881 downregulated miRNAs, we found that miR-767-3p ranked first among them. In order to determine the levels of both miR-767-3p and CLDN18 in lung adenocarcinoma, we collected 39 cases of lung adenocarcinoma and 20 normal tissues. As shown in Figure 1B, miR-767-3p levels were significantly downregulated in the lung adenocarcinoma tissue compared with the normal tissue (p < 0.05). However, CLDN18 expression was also higher in lung adenocarcinoma than in normal tissues (p < 0.05) (Fig. 1C). IHC staining was performed to determine the expression of CLDN18 (Fig. 1D). Interestingly, a strong negative relationship between miR-767-3p and CLDN18 was observed in lung adenocarcinoma (Fig. 1E). In addition, a group of lung adenocarcinoma cell lines, including H1975 and HCC827, was obtained to explore the expression pattern of miR-767-3p and CLDN18, and similar negative correlations were found in the cell lines (Fig. 1F).

Figure 1.

Figure 1

Open in a new tab

MicroRNA 767-3p (miR-767-3p) was downregulated in lung adenocarcinoma and is negatively correlated with claudin 18 (CLDN18) expression. (A) miRNA meta-analysis in YM500v2 (http://ngs.ym.edu.tw/ym500v2/index.php) was performed to detect the differential expression of miRNAs in lung adenocarcinoma compared to the control normal tissue. Group 1: normal tissue, group 2: lung adenocarcinoma. (B) The levels of miR-767-3p in 39 cases of lung adenocarcinoma and 20 cases of normal tissues were detected by qualitative reverse transcriptase polymerase chain reaction (qRT-PCR). (C) qRT-PCR assay was performed to detect the levels of CLDN18 in lung adenocarcinoma tissues and normal tissues. (D) Immunohistochemistry (IHC) staining was used to measure the expression of CLDN18 in lung adenocarcinoma and normal tissues. Scale bar: 200 μM. Data are expressed as mean ± SD. **p < 0.01, compared with normal tissues. (E) The level of miR-767-3p was negatively correlated with CLDN18 in lung adenocarcinoma. (F) The RNA levels of miR-767-3p and CLDN18 were measured in a panel of lung adenocarcinoma cell lines. Data are expressed as mean ± SD. **p < 0.01, compared to BEAS-2B cells.

CLDN18 Was a Target Gene of miR-767-3p

In order to further explore the relationship between CLDN18 and miR-767-3p, we consulted TargetScan (http://www.targetscan.org) to confirm that CLDN18 is one of the miR-767-3p target genes (Fig. 2A). To reveal the correlation between miR-767-3p and CLDN18, we cotransfected 293T cells with CLDN18 WT-, CLDN18 MUT-, miR-767-3p-, or miR-NC-containing vectors. As shown in Figure 2B, the luciferase reporter assays showed that overexpression of miR-767-3p reduced the activity of the CLDN18 WT, whereas the effect of miR-767-3p was eliminated in the cells transfected with CLDN18 MUT. Similar results were obtained in H1975 and HCC827 cells (Fig. 2C). Finally, qRT-PCR and Western blot analysis were performed to further confirm the expression level of CLDN18 in miR-767-3p-overexpressing cells and demonstrate that overexpression of miR-767-3p inhibited the expression of CLDN18 (Fig. 2D). In summary, these results indicated that CLDN18 was a potential target of miR-767-3p in lung adenocarcinoma.

Figure 2.

Figure 2

Open in a new tab

CLDN18 is the target gene of miR-767-3p. (A) The sequence of the miR-767-3p binding site in the 3′-untranslated region (3′-UTR) of CLDN18. (B) Wild-type (WT) and mutant (MUT) sequences of CLDN18 3′-UTR, miR-767-3p, and miR-negative control (NC) were cotransfected into 293T cells The luciferase activity was measured 48 h after transfection. Data are expressed as mean ± SD. **p < 0.01, compared with miR-NC. (C). Dual-luciferase reporter assay was performed in both H1975 and HCC827 cells. Data are expressed as mean ± SD. **p < 0.01, compared with miR-NC. (D). Cells were transfected with miR-767-3p and its corresponding control. The expression of CLDN18 was detected by qRT-PCR (left) and Western blot assays (right). Data are expressed as mean ± SD. **p < 0.01, compared with miR-NC.

Downregulation of CLDN18 Inhibits Tumor Growth and Migration in Lung Adenocarcinoma

To further investigate the role of CLDN18 in lung adenocarcinoma, lung adenocarcinoma cell lines H195 and HCC827 were transfected with shRNA to knock down CLDN18 expression. As expected, the level of CLDN18 was significantly suppressed in CLDN18-specific shRNA (shCLDN18)-transfected H195 and HCC827 cells (Fig. 3A). Then cell proliferation assays were performed to evaluate the effect of CLDN18 on cell growth in vitro, which demonstrated that knockdown of CLDN18 inhibited the proliferation of H195 and HCC827 cells (Fig. 3B). Wound healing assay and Transwell analysis revealed that silencing CLDN18 inhibited migration (Fig. 3C) and invasion (Fig. 3D) of H195 and HCC827 cells. In addition, we established a nude mouse xenograft model to assess the effect of CLDN18 on the growth of lung adenocarcinoma cells H1975 in vivo. As expected, the tumor volume of the CLDN18-silencing group was significantly reduced, compared to the control group (Fig. 3E).

Figure 3.

Figure 3

Open in a new tab

Downregulation of CLDN18 inhibits tumor growth, migration, and invasion in lung adenocarcinoma cells. (A) CLDN18 mRNA levels were determined in cells transfected with short hairpin RNA (shRNA) control (shControl) or CLDN18-specific shRNA (shCLDN18) by qRT-PCR. Data are expressed as mean ± SD. **p < 0.01, compared with shControl. (B). The effect of CLDN18 knockdown on cell proliferation was assessed in H1975 and HCC827 cells. Data are expressed as mean ± SD. *p < 0.05, **p < 0.01, compared with shControl. (C) After shCLDN18 transfection, cell migration was measured by wound healing assay. Data are expressed as mean ± SD. **p < 0.01, compared with shControl. Scale bar: 200 μM. (D). After shCLDN18 transfection, cell invasion was measured by Transwell invasion assay. Data are expressed as mean ± SD. **p < 0.01, compared with shControl. Scale bar: 200 μM. (E). Mice xenograft tumor model was established by subcutaneous inoculation with shCLDN18 H1975 cells or shControl cells (six mice per group).

miR-767-3p Suppressed Growth and Migration of Lung Adenocarcinoma Cells by Targeting CLDN18

Based on the results above, we hypothesized that miR-767-3p downregulation could inhibit tumor growth and migration by modulating CLDN18. To further validate this idea, we transfected H195 and HCC827 cells with miR-NC or miR-767-3p. The results showed that the miR-767-3p inhibited the proliferation of H195 and HCC827 after transfection (Fig. 4A). Wound healing and Transwell assays suggested that the migration ability (Fig. 4B) and invasion capacity (Fig. 4C) of miR-767-3p-overexpressing cells were significantly inhibited. To determine the effect of CLDN18 on miR-767-3p-regulated lung adenocarcinoma cell growth and migration, CLDN18 was stably transfected into H195 and HCC827 cells, and the mRNA and protein levels of CLDN18 were analyzed by qRT-PCR (Fig. 4D) and Western blotting (Fig. 4E). In fact, ectopic expression of CLDN18 rescued cell proliferation, migration, and invasion, which had been inhibited by miR-767-3p (Fig. 4F–H).

Figure 4.

Figure 4

Open in a new tab

miR-767-3p inhibits lung adenocarcinoma cell growth and migration by targeting CLDN18. (A). H195 and HCC827 cells were transfected with miR-767-3p, and cell proliferation was analyzed. Data are expressed as mean ± SD. **p < 0.01, compared with miR-NC. (B) Cells were transfected with miR-767-3p or miR-NC to determine the ability to migrate. Data are expressed as mean ± SD. **p < 0.01, compared with miR-NC. (C) Cells were transfected with miR-767-3p or miR-NC to determine the invasion ability in vitro. Data are expressed as mean ± SD. **p < 0.01, compared with miR-NC. (D). H195 and HCC827 were transfected with a vector containing CLDN18, and the mRNA level of CLDN18 was assessed by qRT-PCR. Data are expressed as mean ± SD. **p < 0.01, compared with vector. (E). H195 and HCC827 cells were transfected with a vector containing CLDN18, and the expression of CLDN18 was analyzed by Western blotting analysis. (F). H195 and HCC827 cells were transfected with miR-767-3p or CLDN18, and cell proliferation was analyzed. (G). H195 and HCC827 were cotransfected with miR-767-3p or CLDN18, and cell migration was analyzed in wound healing assay. (H) Transwell assay was performed to assess the effect of miR-767-3p and CLDN18 on cell invasion. Data are expressed as mean ± SD. *p < 0.05 and **p < 0.01, compared with miR-NC. #p < 0.05 and ##p < 0.01, compared with miR-767-3p + vector.

DISCUSSION

It has been shown that miRNAs function as regulatory factors for specific gene expression and thus affect tumorigenesis, migration, and metastasis14. Previous studies have revealed that miR-767-3p acts as an inhibitor in various types of cancers15. In this study, we found that miR-767-3p was downregulated in lung adenocarcinoma tissue and a panel of cell lines, suggesting that miR-767-3p may inhibit the development of lung adenocarcinoma.

CLDN18, which is encoded by the CLDN18 gene, is a transmembrane protein that plays an important role in tight junctions16. Substantive research has demonstrated that abnormal expression of CLDN18 is associated with tumor progression17. Herein we revealed that CLDN18 was upregulated in lung adenocarcinoma tissue compared to normal tissue, and similar results were found in a panel of lung adenocarcinoma cell lines. A previous study revealed that loss of CLDN18 suppresses tumor cell migration and invasion, which will be the initial step in tumor metastasis18. As an oncogene, CLDN18 is an early stage marker of pancreatic carcinogenesis. However, the role of CLDN18 in tumor growth, migration, and the regulatory mechanism in lung adenocarcinoma needs further investigation. Interestingly, there was a negative correlation between CLDN18 and miR-767-3p expression in lung adenocarcinoma. In fact, the results of luciferase assays showed that miR-767-3p downregulated the expression of CLDN18 by direct binding to CLDN18 3′-UTR, indicating that CLDN18 was the target of miR-767-3p.

We then explored the biological effects of CLDN18 in lung adenocarcinoma cells by transfection with specific shRNA targeting CLDN18. In vitro and in vivo studies have shown that CLDN18 knockdown inhibits lung adenocarcinoma cell growth, migration, and invasion. A previous study suggested that CLDN18 is specifically abnormally expressed in stomach and lung cancers19. Therefore, CLDN18 may be a potential therapeutic target for lung adenocarcinoma. In addition, functional assays showed that miR-767-3p overexpression inhibited tumor growth, migration, and invasion. Notably, overexpression of CLDN18 reversed miR-767-3p-mediated inhibitory effects, suggesting that miR-767-3p regulates tumor growth, migration, and invasion by targeting CLDN18 in lung adenocarcinoma.

In conclusion, our data suggest a significant correlation between miR-767-3p and CLDN18 in lung adenocarcinoma. Downregulation of miR-767-3p and overexpression of CLDN18 were observed in lung adenocarcinoma and cell lines. Overexpression of miR-767-3p inhibits cell proliferation, migration, and invasion of lung adenocarcinoma cells by targeting CLDN18. Therefore, we highlighted the interaction of miR-767-3p and CLDN18 in lung adenocarcinoma development, providing new targets for exploring new therapeutic strategies.

ACKNOWLEDGMENT

The authors declare no conflicts of interest.

Footnotes

The authors declare no conflicts of interest.

REFERENCES

  • 1. Yang Y, Shen X, Li R, Shen J, Zhang H, Yu L, Liu B, Wang L. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC. Oncotarget 2017;8:49773–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Zaporozhchenko IA, Morozkin ES, Skvortsova TE, Ponomaryova AA, Rykova EY, Cherdyntseva NV, Polovnikov ES, Pashkovskaya OA, Pokushalov EA, Vlassov VV, Laktionov PP. Plasma miR-19b and miR-183 as potential biomarkers of lung cancer. PLoS One 2016;11:e0165261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Wu C, Cao Y, He Z, He J, Hu C, Duan H, Jiang J. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med. 2014;232:85–95. [DOI] [PubMed] [Google Scholar]
  • 4. Liang H, Yan X, Pan Y, Wang Y, Wang N, Li L, Liu Y, Chen X, Zhang CY, Gu H, Zen K. MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. Mol Cancer 2015;14:327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Ma Y, Bao C, Kong R, Xing X, Zhang Y, Li S, Zhang W, Jiang J, Zhang J, Qiao Z, Zhang D, Ma Z, Sun L, Zhou B. MicroRNA-361-5p suppresses cancer progression by targeting signal transducer and activator of transcription 6 in non-small cell lung cancer. Mol Medicine Rep. 2015;12:7367–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Gu Y, Liu S, Zhang X, Chen G, Liang H, Yu M, Liao Z, Zhou Y, Zhang CY, Wang T, Wang C, Zhang J, Chen X. Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer. Protein Cell 2017;8:455–66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Liu M, Yang R, Urrehman U, Ye C, Yan X, Cui S, Hong Y, Gu Y, Liu Y, Zhao C, Yan L, Zhang CY, Liang H, Chen X. MiR-19b suppresses PTPRG to promote breast tumorigenesis. Oncotarget 2016;7:64100–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen J, Zhang Y, Lai P, Fan X, Zhou X, Lin J, Li M, Ma W, Luo S, Bai X. miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res. 2014;74:3031–42. [DOI] [PubMed] [Google Scholar]
  • 9. Loriot A, Van Tongelen A, Blanco J, Klaessens S, Cannuyer J, van Baren N, Decottignies A, De Smet C. A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors. Epigenetics 2014;9:1163–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Kim A, Im M, Yim NH, Ma JY. Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production. Sci Rep. 2014;4:6994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Zhong C, Wang K, Liu Y, Lv D, Zheng B, Zhou Q, Sun Q, Chen P, Ding S, Xu Y, Huang H. miR-19b controls cardiac fibroblast proliferation and migration. J Cell Mol Med. 2016;20:1191–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Han Y, Xu H, Cheng J, Zhang Y, Gao C, Fan T, Peng B, Li B, Liu L, Cheng Z. Downregulation of long non-coding RNA H19 promotes P19CL6 cells proliferation and inhibits apoptosis during late-stage cardiac differentiation via miR-19b-modulated Sox6. Cell Biosci. 2016;6:58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Traxl A, Beikbaghban T, Wanek T, Kryeziu K, Pirker C, Mairinger S, Stanek J, Filip T, Sauberer M, Kuntner C, Berger W, Langer O. [11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice. Nucl Med Biol. 2017;52:7–15. [DOI] [PubMed] [Google Scholar]
  • 14. Wei Z, Ye X, Yang X, Zheng A, Huang G, Li W, Wang J, Han X, Meng M, Ni Y. Advanced non small cell lung cancer: Response to microwave ablation and EGFR Status. Eur Radiol. 2017;27:1685–94. [DOI] [PubMed] [Google Scholar]
  • 15. Loriot A, Van Tongelen A, Blanco J, Klaessens S, Cannuyer J, van Baren N, Decottignies A, De Smet C. A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors. Epigenetics 2014;9:1163–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Zhang SJ, Feng JF, Wang L, Guo W, Du YW, Ming L, Zhao GQ. miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells. Digest Dis Sci. 2014;59:1754–63. [DOI] [PubMed] [Google Scholar]
  • 17. Wöll S, Schlitter AM, Dhaene K, Roller M, Esposito I, Sahin U, Türeci Ö. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer 2014;134:731–9. [DOI] [PubMed] [Google Scholar]
  • 18. Halimi SA, Maeda D, Shinozaki-Ushiku A, Koso T, Matsusaka K, Tanaka M, Arimoto T, Oda K, Kawana K, Yano T, Fujii T, Fukayama M. Claudin-18 overexpression in intestinal-type mucinous borderline tumour of the ovary. Histopathology 2013;63:534–44. [DOI] [PubMed] [Google Scholar]
  • 19. Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer 2014;135:2206–14. [DOI] [PubMed] [Google Scholar]

Articles from Oncology Research are provided here courtesy of Tech Science Press

RESOURCES